Anand S Iyer1, Kristen E Holm2, Surya P Bhatt3, Victor Kim4, Gregory L Kinney5, Frederick S Wamboldt6, Michael R Jacobs4, Elizabeth A Regan7, Hilary F Armstrong8, Katherine E Lowe5, Carlos H Martinez9, Mark T Dransfield10, Marilyn G Foreman11, Gen Shinozaki12, Nicola A Hanania13, Robert A Wise14, Barry J Make15, Karin F Hoth16. 1. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, USA; Health Services, Outcomes, and Effectiveness Research Training Program, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: aiyer@uabmc.edu. 2. Department of Medicine, National Jewish Health, Denver, CO, USA; Department of Community and Behavioral Health, Colorado School of Public Health, Aurora, CO, USA. 3. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, USA. 4. Department of Thoracic Medicine and Surgery, Temple University School of Medicine Philadelphia, PA, USA. 5. Department of Epidemiology, Colorado School of Public Health, University of Colorado, Aurora, CO, USA. 6. Department of Medicine, National Jewish Health, Denver, CO, USA; Department of Psychiatry, University of Colorado School of Medicine at the Anschutz Medical Campus, Aurora, CO, USA. 7. Department of Medicine, National Jewish Health, Denver, CO, USA; Department of Epidemiology, Colorado School of Public Health, University of Colorado, Aurora, CO, USA. 8. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. 9. Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA. 10. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, USA; Veterans Affairs Medical Center, Birmingham, AL, USA. 11. Division of Pulmonary and Critical Care Medicine, Morehouse School of Medicine, Atlanta, GA, USA. 12. Department of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, IA, USA; Iowa Neuroscience Institute, Carver College of Medicine, University of Iowa, Iowa City, IA, USA. 13. Division of Pulmonary/Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA. 14. Division of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA. 15. Department of Medicine, National Jewish Health, Denver, CO, USA. 16. Department of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, IA, USA; Iowa Neuroscience Institute, Carver College of Medicine, University of Iowa, Iowa City, IA, USA; Department of Pulmonary, Critical Care, and Sleep Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA. Electronic address: karin-hoth@uiowa.edu.
Abstract
OBJECTIVES: To compare the frequency of anxiety/depressive symptoms and use of anxiolytic-hypnotics/antidepressants in smokers with and without COPD and to identify characteristics associated with having unmedicated symptoms. METHODS: Cross-sectional analysis of ambulatory, current/former smokers ≥10 pack years enrolled in the COPDGene study. We measured anxiety/depressive symptoms using the Hospital Anxiety and Depression Scale (subscales ≥8), recorded anxiolytic-hypnotic/antidepressant use, and defined unmedicated symptoms as elevated anxiety/depressive symptoms and not on medications. Regression analysis identified characteristics associated with having unmedicated symptoms. KEY RESULTS: Of 5331 current/former smokers (45% with and 55% without COPD), 1332 (25.0%) had anxiety/depressive symptoms. Anxiety symptoms were similar in frequency in smokers with and without COPD (19.7% overall), while depressive symptoms were most frequent in severe-very severe COPD at 20.7% (13.1% overall). In the entire cohort, 1135 (21.2%) were on medications. Anxiolytic-hypnotic use was highest in severe-very severe COPD (range 7.6%-12.0%), while antidepressant use showed no significant variation in smokers with and without COPD (range 14.7%-17.1%). Overall, 881 (66% of those with symptoms) had unmedicated symptoms, which was associated with African American race (adjusted OR 2.95, 95% CI 2.25-3.87), male gender (adjusted OR 1.93, 95% CI 1.57-2.36), no health insurance (adjusted OR 2.38, 95% CI 1.30-4.35), severe-very severe COPD (adjusted OR 1.48, 95% CI 1.04-2.11), and higher respiratory symptoms/exacerbation history (adjusted OR 2.21, 95% CI 1.62-3.02). CONCLUSIONS: Significant unmet mental health care needs exist in current and former smokers with and without COPD. One in five have unmedicated symptoms, identified by key demographic and clinical characteristics. PRIMARY FUNDING SOURCE: National Institutes of Health and The COPD Foundation.
OBJECTIVES: To compare the frequency of anxiety/depressive symptoms and use of anxiolytic-hypnotics/antidepressants in smokers with and without COPD and to identify characteristics associated with having unmedicated symptoms. METHODS: Cross-sectional analysis of ambulatory, current/former smokers ≥10 pack years enrolled in the COPDGene study. We measured anxiety/depressive symptoms using the Hospital Anxiety and Depression Scale (subscales ≥8), recorded anxiolytic-hypnotic/antidepressant use, and defined unmedicated symptoms as elevated anxiety/depressive symptoms and not on medications. Regression analysis identified characteristics associated with having unmedicated symptoms. KEY RESULTS: Of 5331 current/former smokers (45% with and 55% without COPD), 1332 (25.0%) had anxiety/depressive symptoms. Anxiety symptoms were similar in frequency in smokers with and without COPD (19.7% overall), while depressive symptoms were most frequent in severe-very severe COPD at 20.7% (13.1% overall). In the entire cohort, 1135 (21.2%) were on medications. Anxiolytic-hypnotic use was highest in severe-very severe COPD (range 7.6%-12.0%), while antidepressant use showed no significant variation in smokers with and without COPD (range 14.7%-17.1%). Overall, 881 (66% of those with symptoms) had unmedicated symptoms, which was associated with African American race (adjusted OR 2.95, 95% CI 2.25-3.87), male gender (adjusted OR 1.93, 95% CI 1.57-2.36), no health insurance (adjusted OR 2.38, 95% CI 1.30-4.35), severe-very severe COPD (adjusted OR 1.48, 95% CI 1.04-2.11), and higher respiratory symptoms/exacerbation history (adjusted OR 2.21, 95% CI 1.62-3.02). CONCLUSIONS: Significant unmet mental health care needs exist in current and former smokers with and without COPD. One in five have unmedicated symptoms, identified by key demographic and clinical characteristics. PRIMARY FUNDING SOURCE: National Institutes of Health and The COPD Foundation.
Authors: Anand S Iyer; J Nicholas Dionne-Odom; Stephanie M Ford; Sheri L Crump Tims; Elizabeth D Sockwell; Nataliya V Ivankova; Cynthia J Brown; Rodney O Tucker; Mark T Dransfield; Marie A Bakitas Journal: Ann Am Thorac Soc Date: 2019-08
Authors: Jacqueline O'Toole; Han Woo; Nirupama Putcha; Christopher B Cooper; Prescott Woodruff; Richard E Kanner; Robert Paine; Russell P Bowler; Alejandro Comellas; Karin F Hoth; Jerry A Krishnan; Meilan Han; Mark Dransfield; Anand S Iyer; David Couper; Stephen P Peters; Gerard Criner; Victor Kim; R Graham Barr; Fernando J Martinez; Nadia N Hansel; Michelle N Eakin Journal: Ann Am Thorac Soc Date: 2022-02
Authors: Anand S Iyer; James Nicholas Dionne-Odom; Dina M Khateeb; Lanier O'Hare; Rodney O Tucker; Cynthia J Brown; Mark T Dransfield; Marie A Bakitas Journal: J Palliat Med Date: 2019-10-29 Impact factor: 2.947
Authors: Hilary C Strollo; Seyed M Nouraie; Karin F Hoth; Craig M Riley; Chad Karoleski; Yingze Zhang; Nicola A Hanania; Russell P Bowler; Jessica Bon; Frank C Sciurba Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-09-03